

The Drugs and Therapeutics Committee

Friday, 11th, May, 2018: 12.30-2.30 PM
Beacon Centre, Seminar Room 1, MPH

Please bring along any refreshments that you may require to the meeting.

AGENDA

- 1 Welcome**
- 2 Apologies for absence**
- 3 Declaration of interests**
- 4 Minutes of last DTC meeting**
- 5 Minutes of APG meetings**
- 6 Matters arising**
 - 6.1 Magnesium sulphate injection 50% - Maternity risk assessment.
 - 6.2 Opicapone – outcomes to be reported at May meeting. Anita Goff.
 - 6.3 Lidocaine patches audit and compliance. Suzanne Carty..
 - 6.4 Ecolab chlorhexidine 2% in 70% alcohol (JB)
 - 6.5 Sunscreen testers for Sun Awareness week stand at MPH (NA).
 - 6.6 Emergency Department extended and advanced practice medicines policy. Martin Horton Consultant/Lead ACP Emergency, MPH.
 - 6.7 SOP (Pharmacy) Guidelines for the Management of Opioid Dependent Individuals in the Acute Hospital Setting. (JB).
- 7 Applications completed by virtual D&TC process**
 - 7.1 Unlicensed Drugs Policy (review, no changes). Approved: 10/03/2017
 - 7.2 Certolizumab IFR request, Paul Thomas. .Approved: 05/03/2018
 - 7.3 Controlled Drugs (CD) Policy reviewed. Accepted (no changes): 29/12/2017.
 - 7.4 Drugs Policy reviewed. Accepted (minor changes): 8/1/2018.
 - 7.5 Ceftazidime / avibactam to treat Achromobacter Zyloxidans in a CF patient. Approved 11/04/2018.
 - 7.6 3,4 Diaminopyridine to treat Lambert Eaton Myasthenic Syndrome (LEMS)
Approved. NHS England funding agreed. 18/04/2018.
- 8 Biosimilars**
 - Humira
 - Herceptin
- 9 Progress of TAs implementation, report from Lincoln Andrews.**
- 10 Nutritional products** Ursula Green, Lead for nutrition and dietetics.
- 11 CDF Drugs (CB)**

12 Early Access to Medicines Scheme (EAMS)

- [Early access to medicines scheme \(EAMS\) scientific opinion](#): Volanesorsen as a treatment of adult patients with familial chylomicronaemia syndrome.

13 Regional Medicines Optimisation Committees (RMOs) (NA)

- First Wave RMOCS discussions: AMR, biosimilars, polypharmacy.
- New position statement: Standardising strengths of high risk, unlicensed oral liquids formulations for anti-TB medicines.
- Drafts for comment: Regional Medicines Optimisation Committee process engagement paper and draft operating model.
- RMO briefing paper on adalimumab
- New workload topics submitted to RMOCS including: homely remedies, low clinical value medicines, shared care and compassionate care / FOC medicines guidance

14 IV Immunglobulins

- 14..1 IAPs – best practice.
- 14..2 **GREY** Q1 to date:
- 14..3 **BLUE** Q1 to date:
- 14..4 Database completion. Q3 2017-18.

15 NICE TAs

NICE TA	Name	Recommendation
504	Pirfenidone for treating idiopathic pulmonary fibrosis	Recommended
505	Ixazomib with lenalidomide and dexamethasone for treating relapsed or refractory multiple myeloma	Recommended
506	Lesinurad for treating chronic hyperuricaemia in people with gout	Not Recommended
507	Sofosbuvir–velpatasvir–voxilaprevir for treating chronic hepatitis C	Recommended
508	Autologous chondrocyte implantation using chondrosphere for treating symptomatic articular cartilage defects of the knee	Non drug
509	Pertuzumab with trastuzumab and docetaxel for treating HER2-positive breast cancer	Recommended
510	Daratumumab monotherapy for treating relapsed and refractory multiple myeloma	Recommended
511	Brodalumab for treating moderate to severe plaque psoriasis	Recommended
512	Tivozanib for treating advanced renal cell carcinoma	Recommended
513	Obinutuzumab for untreated advanced follicular lymphoma	Recommended
514	Regorafenib for previously treated advanced hepatocellular carcinoma	Not recommended
515	Eribulin for treating locally advanced or metastatic breast cancer after 1 chemotherapy regimen	Not recommended
516	Cabozantinib for treating medullary thyroid cancer	Recommended
517	Avelumab for treating metastatic Merkel cell carcinoma	Recommended
518	Tocilizumab for treating giant cell arteritis	Recommended
519	Pembrolizumab for treating locally advanced or metastatic urothelial carcinoma after platinum-containing chemotherapy	Recommended

13 New Drug Requests

- 13.1 Methoxyflurane inhalation vapour (Pentrox™) for emergency pain relief in trauma patients.
- 13.2 Azelastine / Fluticasone nasal spray (Dymista™) for rhinitis. (Christopher Foxton).
- 13.3 Idebenone (Raxone™) for Leber's Hereditary Optic Neuropathy (LHON)
- 13.4 Medicine-related osteonecrosis treatment with triple therapy (Pentoxifylline, tocopherol and clodronate).

14 MHRA Drug Safety Updates – circulation to CSLs: 2/2018 3/2018, 4/2018

15 Other Formulary issues

16 Shared care protocols

- 16.1 Disease Modifying Anti-Rheumatic Drugs (DMARDS)

17 Any other Business

18 Next meeting dates: 27th July, 23rd November.